Prelude Therapeutics reports FY 2022 net loss of $115.4M; cash runway through Q4 2024

Prelude Therapeutics Inc

Net loss of $115.4M ($2.44 per share) vs $111.7M ($2.43 per share) in FY 2021.
Cash and equivalents of $201.7M as of Dec 31, 2022; runway extended through Q4 2024.
R&D expenses $92.9M, G&A $30.7M; both up YoY.
Clinical trial collaboration with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic malignancies.
Bryant D. Lim appointed Chief Legal Officer, effective Feb 20, 2023.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prelude Therapeutics Inc reported financial results for fiscal year ended December 31, 2022.

Period: fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 15, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-007983

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.